Liquid Biopsy: A New Avenue for the Diagnosis of Kidney Disease: Diabetic Kidney Disease, Renal Cancer, and IgA Nephropathy

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2024 Jan 23

PMID 38254967

Authors

Jill Dybiec

Weronika Frak

Joanna Kucmierz

Julita Tokarek

Armanda Wojtasinska

Ewelina Mlynarska

Jacek Rysz

Beata Franczyk

Affiliations

Soon will be listed here.

Abstract

Kidney diseases are some of the most common healthcare problems. As the population of elderly individuals with concurrent health conditions continues to rise, there will be a heightened occurrence of these diseases. Due to the renal condition being one of the longevity predictors, early diagnosis of kidney dysfunction plays a crucial role. Currently, prevalent diagnostic tools include laboratory tests and kidney tissue biopsies. New technologies, particularly liquid biopsy and new detection biomarkers, hold promise for diagnosing kidney disorders. The aim of this review is to present modern diagnostic methods for kidney diseases. The paper focuses on the advances in diagnosing three common renal disorders: diabetic kidney disease, renal cancer, and immunoglobulin A nephropathy. We highlight the significance of liquid biopsy and epigenetic changes, such as DNA methylation, microRNA, piRNAs, and lncRNAs expression, or single-cell transcriptome sequencing in the assessment of kidney diseases. This review underscores the importance of early diagnosis for the effective management of kidney diseases and investigates liquid biopsy as a promising approach.

Citing Articles

Advances in the study of artemisinin and its derivatives for the treatment of rheumatic skeletal disorders, autoimmune inflammatory diseases, and autoimmune disorders: a comprehensive review.

Long Z, Xiang W, Xiao W, Min Y, Qu F, Zhang B Front Immunol. 2024; 15:1432625.

PMID: 39524446 PMC: 11543433. DOI: 10.3389/fimmu.2024.1432625.

References

Allen A, Harper S, Feehally J . Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol. 1995; 100(3):470-4. PMC: 1534466. DOI: 10.1111/j.1365-2249.1995.tb03724.x. View

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View

Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian B, Wyatt R . Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem. 2014; 289(8):5330-9. PMC: 3931088. DOI: 10.1074/jbc.M113.512277. View

Peng W, Koirala P, Mo Y . LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017; 36(41):5661-5667. PMC: 6450570. DOI: 10.1038/onc.2017.184. View

Lou N, Ruan A, Qiu B, Bao L, Xu Y, Zhao Y . miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. Urol Oncol. 2016; 35(1):36.e7-36.e14. DOI: 10.1016/j.urolonc.2016.07.012. View

Mavrogeorgis E, He T, Mischak H, Latosinska A, Vlahou A, Schanstra J . Urinary peptidomic liquid biopsy for non-invasive differential diagnosis of chronic kidney disease. Nephrol Dial Transplant. 2023; 39(3):453-462. PMC: 10899775. DOI: 10.1093/ndt/gfad200. View

Sun X, Dai G, Yu L, Hu Q, Chen J, Guo W . miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci Rep. 2018; 8(1):606. PMC: 5766605. DOI: 10.1038/s41598-017-18739-3. View

Jennette J . The immunohistology of IgA nephropathy. Am J Kidney Dis. 1988; 12(5):348-52. DOI: 10.1016/s0272-6386(88)80022-2. View

Kanzaki G, Tsuboi N, Shimizu A, Yokoo T . Human nephron number, hypertension, and renal pathology. Anat Rec (Hoboken). 2019; 303(10):2537-2543. DOI: 10.1002/ar.24302. View

10.

Petrozza V, Costantini M, Tito C, Giammusso L, Sorrentino V, Cacciotti J . Emerging role of secreted miR-210-3p as potential biomarker for clear cell Renal Cell Carcinoma metastasis. Cancer Biomark. 2019; 27(2):181-188. DOI: 10.3233/CBM-190242. View

11.

Kubiliute R, Jarmalaite S . Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests. Int J Mol Sci. 2021; 22(16). PMC: 8396354. DOI: 10.3390/ijms22168846. View

12.

Xiao W, Wang C, Chen K, Wang T, Xing J, Zhang X . MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2. EBioMedicine. 2020; 51:102622. PMC: 6948168. DOI: 10.1016/j.ebiom.2019.102622. View

13.

Moisoiu T, Iancu S, Burghelea D, Dragomir M, Iacob G, Stefancu A . SERS Liquid Biopsy Profiling of Serum for the Diagnosis of Kidney Cancer. Biomedicines. 2022; 10(2). PMC: 8869590. DOI: 10.3390/biomedicines10020233. View

14.

Fan G, Gong T, Lin Y, Wang J, Sun L, Wei H . Urine proteomics identifies biomarkers for diabetic kidney disease at different stages. Clin Proteomics. 2021; 18(1):32. PMC: 8903606. DOI: 10.1186/s12014-021-09338-6. View

15.

Ledeganck K, Gielis E, Abramowicz D, Stenvinkel P, Shiels P, Van Craenenbroeck A . MicroRNAs in AKI and Kidney Transplantation. Clin J Am Soc Nephrol. 2019; 14(3):454-468. PMC: 6419285. DOI: 10.2215/CJN.08020718. View

16.

Kovesdy C . Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022; 12(1):7-11. PMC: 9073222. DOI: 10.1016/j.kisu.2021.11.003. View

17.

Smith D, Redman J, Fraser D, Bowen T . Identification and detection of microRNA kidney disease biomarkers in liquid biopsies. Curr Opin Nephrol Hypertens. 2023; 32(6):515-521. DOI: 10.1097/MNH.0000000000000927. View

18.

Wang G, Kwan B, Lai F, Chow K, Kam-Tao Li P, Szeto C . Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis Markers. 2011; 30(4):171-9. PMC: 3825242. DOI: 10.3233/DMA-2011-0766. View

19.

Fan Y, Ma X, Li H, Gao Y, Huang Q, Zhang Y . miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating Dicer. Int J Cancer. 2017; 142(3):547-560. DOI: 10.1002/ijc.31050. View

20.

Roberts I . Pathology of IgA nephropathy. Nat Rev Nephrol. 2014; 10(8):445-54. DOI: 10.1038/nrneph.2014.92. View